JVM Records High Sales and Profit in Q1 with Strong Global Market Penetration

JVM, a subsidiary of Hanmi Science, 1Quarterly Consolidated Sales 377billion won, operating profit 75billion won, net profit 69achieved a billion 27said the day. Sales compared to the previous year 19.5%, operating profit 69.4%, net profit 87.7% the number that has grown.

JVM is strengthening its global market penetration in accordance with the expansion of the automatic drug preparation market. 1Quarterly exports compared to the same period last year 25.3% increased 183reported to have recorded billions of. Sales share by market 51.5%, Export 48.5%is, By export region, North America 17.5%, europe 25%, etc 6%was.

In particular, JVM Europe Corporation(FMV EU)compared to the same period last year 30.6% increased 81recorded billions of dollars in sales, operating profit and net profit 204.7%, 150.9% The company explained that it showed a large growth trend as it increased..

According to the company, JVM 2016Growing after being incorporated into Hanmi Science, the holding company of Hanmi Group, in 2011. Hanmi Pharmaceuticals and Online Pharm, affiliates of Hanmi Science, are in charge of JVM’s overseas and domestic business, respectively., JVM is dedicated to developing next-generation new products. R&Dand focused on production. Hanmi Pharm is currently a global partner company 34through the opening 59JVM products are sold in 20 countries..

JVM official “Along with the spread of the automatic pouch-type medicine dispensing method worldwide, the future value of JVM is also rapidly growing.”as “As a key growth engine that will lead the future healthcare market, we will further develop JVM’s unrivaled competitiveness.”said.